| Name | Title | Contact Details |
|---|
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.
With over 1,975 employees, it has a presence, through its 13 affiliates in Europe and United States.
Neuromed Pharmaceuticals Ltd. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novel therapeutics for metabolic and endocrine disorders
Ward Drug Co Of Nashville is a Nashville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.